News for uniQure N.V. (0EE0.L)

Published at

May 29, 2025 3:00 PM

by gurufocus.com

neutral

neutral

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to

UQ1.DE QURE 0EE0.L

Read more →
Published at

May 29, 2025 1:11 PM

by manilatimes.net

neutral

neutral

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

**media[640256]**

UQ1.DE QURE 0EE0.L

Read more →
Published at

May 28, 2025 10:56 AM

by seekingalpha.com

positive

positive

uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE)

uniQure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs AMT-130’s BLA. See more on QURE here.

UQ1.DE QURE 0EE0.L

Read more →
Published at

May 19, 2025 3:00 PM

by gurufocus.com

mixed

mixed

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

CRBP AKTX 0SZI.L UQ1.DE QURE 0EE0.L

Read more →
Published at

May 10, 2025 4:16 AM

by seekingalpha.com

mixed

mixed

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsChiara Russo - Senior Director, Investor RelationsMatt...

UQ1.DE 0EE0.L QURE

Read more →
Published at

May 9, 2025 3:00 PM

by gurufocus.com

neutral

neutral

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generall

UQ1.DE QURE 0EE0.L

Read more →
Published at

May 9, 2025 1:21 PM

by manilatimes.net

neutral

neutral

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

**media[620252]**

UQ1.DE QURE 0EE0.L

Read more →
Published at

May 6, 2025 12:00 AM

by gurufocus.com

neutral

neutral

uniQure to Announce First Quarter 2025 Financial Results

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWS

UQ1.DE QURE 0EE0.L

Read more →
Published at

Apr 21, 2025 4:36 PM

by benzinga.com

mixed

mixed

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Beam Therapeutics (NASDAQ:BEAM), B2Gold (AMEX:BTG)

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

WWW UQ1.DE REPL RCKT QURE PCRX NTLA MVST ERAS CLSK BTO.TO BTGN.MX BTG BEAM 0QYN.L 0JBU.L 0EE0.L VERV

Read more →
Published at

Apr 17, 2025 4:30 PM

by benzinga.com

positive

positive

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr (NASDAQ:CAR), Capricor Therapeutics (NASDAQ:CAPR)

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V. QURE rose sharply during Thursday's session afte...

ZGY.DE UQ1.DE QURE LLY.MX LLY.DE LLY.BA LLY LILY34.SA IIIN HTZZ HTZGQ HTZ FIS.MX FIS F1NI34.SA EVTCY EVTA.DE EVT.DE EVOTF DT3.DE DLTR.MX DLTR CLPT CAR.MX CAR.BA CAR CAPR 0Q1G.L 0J4Z.L 0ILW.L 0IC8.L 0HK4.L 0EE0.L

Read more →
Published at

Apr 17, 2025 3:00 PM

by gurufocus.com

positive

positive

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulator

UQ1.DE QURE 0EE0.L

Read more →
Published at

Apr 17, 2025 2:30 PM

by gurufocus.com

positive

positive

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News

uniQure (QURE) receives FDA Breakthrough Therapy designation for AMT-130, potentially accelerating regulatory approval for Huntington's disease treatment

UQ1.DE QURE 0EE0.L

Read more →
Published at

Apr 17, 2025 1:41 PM

by manilatimes.net

positive

positive

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

**media[597939]**

UQ1.DE QURE 0EE0.L

Read more →
Published at

Feb 27, 2025 2:00 PM

by gurufocus.com

positive

positive

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease;

UQ1.DE QURE 0EE0.L

Read more →
Published at

Feb 27, 2025 1:19 PM

by manilatimes.net

mixed

mixed

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

**media[552098]**

UQ1.DE QURE 0EE0.L COWNL COWN

Read more →
Published at

Feb 26, 2025 7:47 AM

by seekingalpha.com

positive

positive

uniQure N.V. Stock: A Potential Huntington's Play (NASDAQ:QURE)

uniQure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting measures and analyst support.

UQ1.DE QURE 0EE0.L

Read more →
Published at

Jan 30, 2025 1:49 PM

by manilatimes.net

positive

positive

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

**media[528038]**

UQ1.DE QURE 0EE0.L

Read more →
Published at

Jan 13, 2025 10:17 PM

by insidermonkey.com

neutral

neutral

Here’s Why uniQure N.V. (QURE) Is Skyrocketing

One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.

UQ1.DE QURE 0EE0.L

Read more →
Published at

Jan 12, 2025 2:01 AM

by insidermonkey.com

positive

positive

Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold in 2025. In this article, we are going to take a look at where uniQure N.V.

UQ1.DE QURE 0EE0.L

Read more →
Published at

Jan 8, 2025 1:49 PM

by rttnews.com

positive

positive

UniQure Prices 4.4 Mln Offering At $17/Share, Stock Down In Pre-Market

uniQure N.V. (QURE), Wednesday announced the pricing of underwritten public offering of around 4.4 million shares at $17 per share, raising a total of nearly $75 million.

UQ1.DE QURE 0EE0.L

Read more →